Invention Grant
- Patent Title: Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
-
Application No.: US17168325Application Date: 2021-02-05
-
Publication No.: US11732019B2Publication Date: 2023-08-22
- Inventor: Mark Macielag , Raymond J. Patch , Rui Zhang , Martin A. Case , Mark J. Wall , Yue-Mei Zhang
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Agency: Seed IP Law Group LLP
- Main IPC: C07K14/575
- IPC: C07K14/575 ; A61K47/68 ; C07K16/24 ; A61K9/00 ; A61K38/17 ; A61K38/26 ; C07K1/06 ; C07K1/107 ; A61K47/64 ; A61P3/10 ; A61K49/00 ; C07K1/12 ; C07K1/18 ; C07K5/02 ; A61K47/60 ; A61P3/08 ; A61P3/00 ; A61P3/04 ; A61P3/06 ; A61K38/22 ; A61K45/06 ; C07K16/00 ; A61K38/00 ; A61K39/00
Abstract:
The present invention comprises compounds of Formula I.
wherein:
Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
wherein:
Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
Public/Granted literature
- US20210206822A1 Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors Public/Granted day:2021-07-08
Information query
